THE GLOBAL DIGITAL BIOMARKERS MARKET IS EXPECTED TO REACH USD 8.58 BILLION BY 2029 FROM USD 2.49 BILLION IN 2023, GROWING AT A CAGR OF 22.86% DURING THE FORECAST PERIOD.

The Digital Biomarkers Market Size, Share, & Trends Analysis Report By

  • Product Type: Wearables & Sensors and Mobile Application & Software
  • Application: Cardiology, Pulmonology, Neurology, and Others
  • Clinical Practice: Diagnostic, Monitoring, Prognostic, Predictive, and Others
  • End-users: Healthcare Companies, Healthcare Providers, and Others
  • Geography: North America, Europe, APAC, Latin America, and Middle East & Africa

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

352 Pages

icon-table

174 Tables

icon-chart

113 Charts

icon-region

5 Regions

icon-country

22 Countries

icon-company

20 Companies

icon-market

5 Market Segment

DIGITAL BIOMARKERS MARKET REPORT SCOPE

Report Attribute Details
Market Size (2029) USD 8.58 Billion
Market Size (2023) USD 2.49 Billion
CAGR (2023-2029) 22.86%
Historic Year 2020-2022
BASE YEAR 2023
Forecast Year 2024-2029
Market Segments Product Type, Application, Clinical Practice, End-user, and Geography
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
KEY PLAYERS ActiGraph, AliveCor, Amgen, Biogen, and Koneksa Health

MARKET OUTLOOK

The global digital biomarkers market was valued at USD 2.49 billion in 2023 and is expected to reach USD 8.58 billion by 2029, growing at a CAGR of 22.86%. The global market is experiencing rapid growth and transformation, driven by technological advancements, increasing healthcare digitization, and a growing demand for more personalized healthcare solutions. The implications of digital biomarkers are far-reaching and transformative. The digital biomarkers market can revolutionize early disease detection, chronic disease management, drug development, and clinical research. With the aid of wearable devices, smartphone apps, and other digital tools, healthcare providers can monitor patients remotely, ensuring early intervention and personalized care. Additionally, pharmaceutical companies can use digital biomarkers to enhance drug development by accurately tracking the efficacy and safety of investigational therapies.

Digital biomarkers represent a paradigm shift in healthcare, leveraging the ever-expanding capabilities of digital technology to collect, analyze, and interpret an individual's health-related data. These markers extend far beyond traditional vital signs and laboratory tests, offering a comprehensive view of a person's health by tapping into a wealth of physiological, behavioral, and environmental data. Unlike conventional biomarkers, such as cholesterol levels or blood pressure readings, digital biomarkers are dynamic and continuously generated, providing real-time insights into an individual's well-being and health trends.

MARKET TRENDS & DRIVERS

Rise in Digitized Virtual Clinical Research
The rise in digitized virtual clinical research is a significant trend in the global digital biomarkers market, driven by advances in remote monitoring technologies and the need for more efficient, patient-centric clinical trials. This trend allows for greater patient participation and real-world data collection, accelerating the development and validation of digital biomarkers for various healthcare applications.

Increasing Focus on Drug Development Using Digital Biomarkers
The global digital biomarkers market is witnessing a notable trend with an increasing focus on drug development. Pharmaceutical and biotech companies are leveraging digital biomarkers to enhance clinical trials, improve patient recruitment, and expedite the development of new therapies, harnessing the power of real-time data for evidence-based decision-making. This trend represents a significant shift towards more efficient and data-driven drug development processes, benefiting patients and the pharmaceutical industry.

Expanding Applications of Digital Biomarkers in Mental Health
The digital markers are increasingly used to monitor and analyze behavioral patterns, providing valuable insights into stress levels, mood fluctuations, and sleep quality, supporting the proactive management of mental health conditions. This trend reflects the broader shift towards personalized, data-driven mental healthcare.

Growing Collaborations & Partnerships Among Vendors
A prominent trend in the global digital biomarkers market is the increasing number of vendor collaborations and partnerships. These partnerships combine expertise, technologies, and resources, fostering innovation and expanding the application of digital biomarkers across various healthcare sectors, ultimately benefiting patients and healthcare systems.

Rise in Aging Population & Prevalence of Chronic Diseases
The aging population and the increasing prevalence of chronic diseases have become pivotal drivers of the market. As the elderly demographic expands and chronic conditions become more widespread, there is a growing need for digital solutions that enable remote monitoring, early detection, and personalized health management, making digital biomarkers an essential component of modern healthcare.

Advancements in Remote Patient Monitoring
Advancements in remote patient monitoring, enabled by digital biomarkers, are revolutionizing healthcare by providing real-time patient data, enhancing early intervention, and optimizing chronic disease management. This technology-driven shift is fueling the growth of the global digital biomarkers market as it offers more personalized, efficient, and cost-effective healthcare solutions.

Growing Culture of Digital Health & Shift Toward Outpatient Care
The growing culture of digital health is fostering a shift toward outpatient care, where patients can monitor and manage their health remotely. This shift is a driving force behind the global digital biomarkers market, as digital biomarkers enable real-time patient monitoring and data-driven healthcare, improving outcomes and reducing the burden on traditional healthcare facilities.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCT TYPE
The global digital biomarkers market by product type is segmented into wearables & sensors and mobile applications & software. The wearables & sensors segment dominated the segmental share in 2023 and is expected to register the highest segmental CAGR in the global digital biomarkers market during the forecast period. Wearable devices include smartwatches, fitness trackers, and other sensor-equipped devices that collect continuous health data, such as heart rate, activity levels, and sleep patterns. Wearables are a primary source of physiological data, providing insights into various health parameters. They are crucial in remote patient monitoring, clinical trials, and preventive healthcare. Sensors are used to measure biomarkers in bodily fluids, offering insights into various health conditions. They find applications in diagnostics, disease monitoring, and research studies.

Mobile applications and software applications designed for smartphones and tablets enable users to monitor and manage their health. These systems often incorporate wearable devices and sensors to collect continuous patient vital signs and health status data. They support the management of chronic diseases and post-operative care. They contribute to disease management and wellness initiatives.

INSIGHTS BY APPLICATION
The global digital biomarkers market by application is segmented into cardiology, pulmonology, and neurology. In 2023, cardiology accounted for the major segmental share of the global market, followed by pulmonology, neurology, and others. The field of cardiology has witnessed significant advancements over the years, leading to a better understanding of cardiovascular diseases (CVDs) and improved diagnostic and treatment options. In recent times, digital biomarkers have emerged as a revolutionary tool that is transforming the cardiology landscape. Digital biomarkers are measurable, physiological, behavioral, or molecular data that can be collected and analyzed using digital health technologies. These biomarkers offer new ways to diagnose, monitor, and treat CVDs, ultimately improving patient outcomes and enhancing healthcare efficiency.

Digital biomarkers are increasingly used in the assessment and management of neurological disorders such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis. Wearable devices and mobile applications help track movement patterns, cognitive functions, and other relevant data. Thus, the neurology segment is expected to register the highest CAGR in the global digital biomarkers market during the forecast period. Further, other applications of digital biomarkers include sleep disorders, diabetes, musculoskeletal disorders, immunology, rare diseases, and cancer. Wearable devices equipped with sensors provide insights into sleep patterns, duration, and quality. Digital biomarkers assist in the diagnosis and management of sleep disorders such as insomnia and sleep apnea. In cancer care, digital biomarkers aid in monitoring patients undergoing treatment, assessing symptoms, and tracking side effects.

INSIGHTS BY CLINICAL PRACTICE
The diagnostic clinical practice segment held the most prominent share of the global digital biomarkers market, accounting for over 34% in 2023. Diagnostic digital biomarkers are increasingly utilized to identify specific diseases, disorders, or physiological conditions through digital data analysis. This could involve patterns in biometric data, imaging, or other digital health inputs. Monitoring digital biomarkers involves the real-time or periodic assessment of digital data to track changes in health status, disease progression, or treatment response. Wearable devices and continuous monitoring platforms are often used. Predictive digital biomarkers help anticipate the occurrence of specific health events, guiding preventive measures or interventions. Predictive digital biomarkers are valuable in identifying at-risk populations.

INSIGHTS BY END-USERS
The global digital biomarkers market by end-user is segmented into healthcare companies, healthcare providers, and others. The healthcare companies segment held the most significant global market share in 2023. In the modern era of healthcare, integrating technology and data-driven solutions has revolutionized patient care, disease management, and drug development. Digital biomarkers, a novel concept in the field of healthcare, have gained prominence as a valuable tool for monitoring and diagnosing various medical conditions. Healthcare companies, including pharmaceutical firms and health tech startups, are increasingly recognizing the potential of digital biomarkers to improve patient outcomes and reduce costs. Another significant advantage of digital biomarkers is their potential to reduce healthcare costs. By adopting digital monitoring tools, healthcare companies can decrease the need for frequent in-person visits and hospital admissions.

GEOGRAPHICAL ANALYSIS

North America dominated the global digital biomarkers market share, accounting for over 46% in 2023. The market in North America is witnessing remarkable growth and innovation, driven by advancements in technology, a growing emphasis on personalized healthcare, and the increasing adoption of wearable devices and digital health solutions. Factors such as an aging population, increasing healthcare costs, and a shift towards value-based care have driven the adoption of digital biomarkers. Additionally, the COVID-19 pandemic accelerated the acceptance of remote monitoring and telehealth, further boosting the industry's growth.

The European digital biomarkers market is characterized by a focus on research and development, collaborations between academia and industry, and a growing awareness of the benefits of digital health technologies. Further, in APAC, increasing investments in healthcare infrastructure, a growing aging population, and the rising prevalence of chronic diseases contribute to the market's expansion. In Latin America & the Middle East & Africa, the industry is influenced by improving healthcare access, a growing middle class, and increased awareness of preventive healthcare measures.

VENDOR LANDSCAPE

The global digital biomarkers market is experiencing rapid growth, revolutionizing the healthcare industry by incorporating technology to collect, analyze, and interpret various digital health data. As vendors strive to develop more accurate and effective digital biomarkers, healthcare professionals gain access to advanced tools for diagnosing and managing various medical conditions. Ultimately, this contributes to improved patient outcomes and a more efficient healthcare system. Data privacy and security have become paramount with the increasing amount of personal health data being collected. Companies that can offer robust security measures and maintain the trust of their users will have a competitive edge.

The key global digital biomarkers market players are ActiGraph, AliveCor, Amgen, Biogen, and Koneksa Health. One of the key players in the digital biomarkers market is ActiGraph, which develops and manufactures wearable activity monitors and accelerometers that accurately capture data on physical activity, sleep, and other health-related parameters. These devices are widely used in clinical trials, research studies, and healthcare settings to track patient progress and outcomes. ActiGraph provides comprehensive software solutions for data collection, management, and analysis. Researchers and healthcare professionals can access the company’s software to streamline data processing, perform in-depth analyses, and generate insights.

Frequently Asked Questions

How big is the digital biomarkers market?

The global digital biomarkers market was valued at USD 2.49 billion in 2023 and is expected to reach USD 8.58 billion by 2029.

What is the growth rate of the global digital biomarkers market?

The global digital biomarkers market is expected to grow at a CAGR of 22.86% from 2023 to 2029.

Which region dominates the global digital biomarkers market share?

North America held the most prominent global digital biomarkers market share, accounting for over 46% of the global share in 2023.

What are the significant trends in the digital biomarkers industry?

The rise in digitized virtual clinical research, increasing focus on drug development using digital biomarkers, expanding applications of digital biomarkers in mental health, and growing collaborations & partnerships among vendors are significant trends in the digital biomarkers industry.

Who are the key players in the global digital biomarkers market?

ActiGraph, AliveCor, Amgen, Biogen, and Koneksa Health are the key players in the global digital biomarkers market.

Download Free Sample

The global digital biomarkers market size is expected to grow at a CAGR of approximately 22.86% from 2023 to 2029.

The following factors are likely to contribute to the growth of the digital biomarkers market during the forecast period:

  • Rise in Aging Population & Prevalence of Chronic Diseases
  • Advancements in Remote Patient Monitoring
  • Growing Culture of Digital Health & Shift Toward Outpatient Care
  • Growing Usage of Wireless & Wearable Digital Monitoring Technologies

Base Year: 2023

Forecast Year: 2024-2029

The report considers the present scenario of the global digital biomarkers market and its market dynamics for 2024−2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.

Key Company Profiles

  • ActiGraph
    • Business Overview
    • Product Offerings
    • Key Strategies
    • Key Strengths
    • Key Opportunities
  • AliveCor
  • Amgen
  • Biogen
  • Koneksa Health

Other Prominent Vendors

  • Adherium
    • Business Overview
    • Product Offerings
  • Aural Analytics
  • Biofourmis
  • Clario
  • Empatica
  • Feel Therapeutics
  • Gero.ai
  • IXICO
  • Obvio Health
  • Owkin
  • Precordior
  • ResApp Health
  • Rockley Photonics
  • Sonde Health
  • VivoSense

Segmentation by Product Type

  • Wearables & Sensors
  • Mobile Application & Software

Segmentation by Application

  • Cardiology
  • Pulmonology
  • Neurology
  • Others

Segmentation by Clinical Practice

  • Diagnostic
  • Monitoring
  • Prognostic
  • Predictive
  • Others

Segmentation by End-users

  • Healthcare Companies
  • Healthcare Providers
  • Others

Segmentation by Geography

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • The U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • APAC
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • South Africa

1 SCOPE & COVERAGE
1.1. MARKET DEFINITION
1.1.1. INCLUSIONS
1.1.2. EXCLUSIONS
1.1.3. MARKET ESTIMATION CAVEATS
1.2. MARKET BY SEGMENTATION
1.2.1. MARKET BY PRODUCT TYPE
1.2.2. MARKET BY APPLICATION
1.2.3. MARKET BY CLINICAL PRACTICE
1.2.4. MARKET BY END-USER
1.2.5. MARKET SEGMENTATIONS COVERED
1.2.6. REGIONS & COUNTRIES COVERED
1.2.7. BASE YEAR
1.3. MARKET DERIVATION

2 PREMIUM INSIGHTS
2.1 OPPORTUNITY POCKETS
2.2 MARKET OPPORTUNITY BY GEOGRAPHY
2.3 MARKET OPPORTUNITY BY PRODUCT TYPE
2.4 MARKET OPPORTUNITY BY APPLICATION
2.5 MARKET OPPORTUNITY BY CLINICAL PRACTICE
2.6 MARKET OPPORTUNITY BY END-USER
2.7 OVERVIEW
2.8 GEOGRAPHY INSIGHTS
2.9 PRODUCT INSIGHTS
2.10 APPLICATION INSIGHTS
2.11 CLINICAL PRACTICE INSIGHTS
2.12 END-USER INSIGHTS

3 MARKET AT A GLANCE
4 INTRODUCTION
4.1 OVERVIEW

5 MARKET OPPORTUNITIES & TRENDS
5.1 RISE IN DIGITIZED VIRTUAL CLINICAL RESEARCH
5.2 INCREASING FOCUS ON DRUG DEVELOPMENT USING DIGITAL BIOMARKERS
5.3 EXPANDING APPLICATIONS OF DIGITAL BIOMARKERS IN MENTAL HEALTH
5.4 GROWING COLLABORATIONS & PARTNERSHIPS AMONG VENDORS

6 MARKET GROWTH ENABLERS
6.1 RISE IN AGING POPULATION & PREVALENCE OF CHRONIC DISEASES
6.2 ADVANCES IN REMOTE PATIENT MONITORING
6.3 GROWING CULTURE OF DIGITAL HEALTH & SHIFT TOWARD OUTPATIENT CARE
6.4 GROWING USE OF WIRELESS & WEARABLE DIGITAL MONITORING TECHNOLOGIES

7 MARKET RESTRAINTS
7.1 DATA SECURITY & PRIVACY CONCERN
7.2 LOW ADOPTION RATE
7.3 LACK OF REGULATORY STANDARDIZATION

8 MARKET LANDSCAPE
8.1 MARKET OVERVIEW
8.2 MARKET SIZE & FORECAST
8.3 FIVE FORCES ANALYSIS
8.3.1 THREAT OF NEW ENTRANTS
8.3.2 BARGAINING POWER OF SUPPLIERS
8.3.3 BARGAINING POWER OF BUYERS
8.3.4 THREAT OF SUBSTITUTES
8.3.5 COMPETITIVE RIVALRY

9 PRODUCT TYPE
9.1 MARKET SNAPSHOT & GROWTH ENGINE
9.2 MARKET OVERVIEW
9.3 WEARABLES & SENSORS
9.3.1 MARKET OVERVIEW
9.3.2 MARKET SIZE & FORECAST
9.3.3 WEARABLES & SENSORS MARKET BY GEOGRAPHY
9.4 MOBILE APPLICATION & SOFTWARE
9.4.1 MARKET OVERVIEW
9.4.2 MARKET SIZE & FORECAST
9.4.3 MOBILE APPLICATION & SOFTWARE MARKET BY GEOGRAPHY

10 APPLICATION
10.1 MARKET SNAPSHOT & GROWTH ENGINE
10.2 MARKET OVERVIEW
10.3 CARDIOLOGY
10.3.1 MARKET OVERVIEW
10.3.2 MARKET SIZE & FORECAST
10.3.3 CARDIOLOGY MARKET BY GEOGRAPHY
10.4 PULMONOLOGY
10.4.1 MARKET OVERVIEW
10.4.2 MARKET SIZE & FORECAST
10.4.3 PULMONOLOGY MARKET BY GEOGRAPHY
10.5 NEUROLOGY
10.5.1 MARKET OVERVIEW
10.5.2 MARKET SIZE & FORECAST
10.5.3 NEUROLOGY MARKET BY GEOGRAPHY
10.6 OTHER
10.6.1 MARKET OVERVIEW
10.6.2 MARKET SIZE & FORECAST
10.6.3 OTHER MARKET BY GEOGRAPHY

11 CLINICAL PRACTICE
11.1 MARKET SNAPSHOT & GROWTH ENGINE
11.2 MARKET OVERVIEW
11.3 DIAGNOSTIC
11.3.1 MARKET OVERVIEW
11.3.2 MARKET SIZE & FORECAST
11.3.3 DIAGNOSTIC MARKET BY GEOGRAPHY
11.4 MONITORING
11.4.1 MARKET OVERVIEW
11.4.2 MARKET SIZE & FORECAST
11.4.3 MONITORING MARKET BY GEOGRAPHY
11.5 PROGNOSTIC
11.5.1 MARKET OVERVIEW
11.5.2 MARKET SIZE & FORECAST
11.5.3 PROGNOSTIC MARKET BY GEOGRAPHY
11.6 PREDICTIVE
11.6.1 MARKET OVERVIEW
11.6.2 MARKET SIZE & FORECAST
11.6.3 PREDICTIVE MARKET BY GEOGRAPHY
11.7 OTHER
11.7.1 MARKET OVERVIEW
11.7.2 MARKET SIZE & FORECAST
11.7.3 OTHER MARKET BY GEOGRAPHY

12 END-USER
12.1 MARKET SNAPSHOT & GROWTH ENGINE
12.2 MARKET OVERVIEW
12.3 HEALTHCARE COMPANIES
12.3.1 MARKET OVERVIEW
12.3.2 MARKET SIZE & FORECAST
12.3.3 HEALTHCARE COMPANIES MARKET BY GEOGRAPHY
12.4 HEALTHCARE PROVIDERS
12.4.1 MARKET OVERVIEW
12.4.2 MARKET SIZE & FORECAST
12.4.3 HEALTHCARE PROVIDERS MARKET BY GEOGRAPHY
12.5 OTHER
12.5.1 MARKET OVERVIEW
12.5.2 MARKET SIZE & FORECAST
12.5.3 OTHER MARKET BY GEOGRAPHY

13 GEOGRAPHY
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 GEOGRAPHIC OVERVIEW

14 NORTH AMERICA
14.1 MARKET OVERVIEW
14.2 MARKET SIZE & FORECAST
14.2.1 NORTH AMERICA MARKET BY PRODUCT TYPE
14.2.2 NORTH AMERICA MARKET BY APPLICATION
14.2.3 NORTH AMERICA MARKET BY CLINICAL PRACTICE
14.2.4 NORTH AMERICA MARKET BY END-USER
14.3 KEY COUNTRIES
14.4 US: MARKET SIZE & FORECAST
14.5 CANADA: MARKET SIZE & FORECAST

15 EUROPE
15.1 MARKET OVERVIEW
15.2 MARKET SIZE & FORECAST
15.2.1 EUROPE MARKET BY PRODUCT TYPE
15.2.2 EUROPE MARKET BY APPLICATION
15.2.3 EUROPE MARKET BY CLINICAL PRACTICE
15.2.4 EUROPE MARKET BY END-USER
15.3 KEY COUNTRIES
15.4 GERMANY: MARKET SIZE & FORECAST
15.5 UK: MARKET SIZE & FORECAST
15.6 FRANCE: MARKET SIZE & FORECAST
15.7 ITALY: MARKET SIZE & FORECAST
15.8 SPAIN: MARKET SIZE & FORECAST
15.9 RUSSIA: MARKET SIZE & FORECAST
15.10 NETHERLANDS: MARKET SIZE & FORECAST

16 APAC
16.1 MARKET OVERVIEW
16.2 MARKET SIZE & FORECAST
16.2.1 APAC MARKET BY PRODUCT TYPE
16.2.2 APAC MARKET BY APPLICATION
16.2.3 APAC MARKET BY CLINICAL PRACTICE
16.2.4 APAC MARKET BY END-USER
16.3 KEY COUNTRIES
16.4 JAPAN: MARKET SIZE & FORECAST
16.5 CHINA: MARKET SIZE & FORECAST
16.6 INDIA: MARKET SIZE & FORECAST
16.7 SOUTH KOREA: MARKET SIZE & FORECAST
16.8 AUSTRALIA: MARKET SIZE & FORECAST

17 LATIN AMERICA
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.2.1 LATIN AMERICA MARKET BY PRODUCT TYPE
17.2.2 LATIN AMERICA MARKET BY APPLICATION
17.2.3 LATIN AMERICA MARKET BY CLINICAL PRACTICE
17.2.4 LATIN AMERICA MARKET BY END-USER
17.3 KEY COUNTRIES
17.4 BRAZIL: MARKET SIZE & FORECAST
17.5 MEXICO: MARKET SIZE & FORECAST
17.6 ARGENTINA: MARKET SIZE & FORECAST
17.7 COLOMBIA: MARKET SIZE & FORECAST

18 MIDDLE EAST & AFRICA
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.2.1 MIDDLE EAST & AFRICA MARKET BY PRODUCT TYPE
18.2.2 MIDDLE EAST & AFRICA MARKET BY APPLICATION
18.2.3 MIDDLE EAST & AFRICA MARKET BY CLINICAL PRACTICE
18.2.4 MIDDLE EAST & AFRICA MARKET BY END-USER
18.3 KEY COUNTRIES
18.4 TURKEY: MARKET SIZE & FORECAST
18.5 SAUDI ARABIA: MARKET SIZE & FORECAST
18.6 UAE: MARKET SIZE & FORECAST
18.7 SOUTH AFRICA: MARKET SIZE & FORECAST

19 COMPETITIVE LANDSCAPE
19.1 COMPETITION OVERVIEW
19.2 MARKET SHARE ANALYSIS
19.2.1 ACTIGRAPH
19.2.2 ALIVECOR
19.2.3 AMGEN
19.2.4 BIOGEN
19.2.5 KONEKSA HEALTH

20 KEY COMPANY PROFILES
20.1 ACTIGRAPH
20.1.1 BUSINESS OVERVIEW
20.1.2 PRODUCT OFFERINGS
20.1.3 KEY STRATEGIES
20.1.4 KEY STRENGTHS
20.1.5 KEY OPPORTUNITIES
20.2 ALIVECOR
20.2.1 BUSINESS OVERVIEW
20.2.2 PRODUCT OFFERINGS
20.2.3 KEY STRATEGIES
20.2.4 KEY STRENGTHS
20.2.5 KEY OPPORTUNITIES
20.3 AMGEN
20.3.1 BUSINESS OVERVIEW
20.3.2 PRODUCT OFFERINGS
20.3.3 KEY STRATEGIES
20.3.4 KEY STRENGTHS
20.3.5 KEY OPPORTUNITIES
20.4 BIOGEN
20.4.1 BUSINESS OVERVIEW
20.4.2 PRODUCT OFFERINGS
20.4.3 KEY STRATEGIES
20.4.4 KEY STRENGTHS
20.4.5 KEY OPPORTUNITIES
20.5 KONEKSA HEALTH
20.5.1 BUSINESS OVERVIEW
20.5.2 PRODUCT OFFERINGS
20.5.3 KEY STRATEGIES
20.5.4 KEY STRENGTHS
20.5.5 KEY OPPORTUNITIES

21 OTHER PROMINENT VENDORS
21.1 ADHERIUM
21.1.1 BUSINESS OVERVIEW
21.1.2 PRODUCT OFFERINGS
21.2 AURAL ANALYTICS
21.2.1 BUSINESS OVERVIEW
21.2.2 PRODUCT OFFERINGS
21.3 BIOFOURMIS
21.3.1 BUSINESS OVERVIEW
21.3.2 PRODUCT OFFERINGS
21.4 CLARIO
21.4.1 BUSINESS OVERVIEW
21.4.2 PRODUCT OFFERINGS
21.5 EMPATICA
21.5.1 BUSINESS OVERVIEW
21.5.2 PRODUCT OFFERINGS
21.6 FEEL THERAPEUTICS
21.6.1 BUSINESS OVERVIEW
21.6.2 PRODUCT OFFERINGS
21.7 GERO.AI
21.7.1 BUSINESS OVERVIEW
21.7.2 PRODUCT OFFERINGS
21.8 IXICO
21.8.1 BUSINESS OVERVIEW
21.8.2 PRODUCT OFFERINGS
21.9 OBVIO HEALTH
21.9.1 BUSINESS OVERVIEW
21.9.2 PRODUCT OFFERINGS
21.10 OWKIN
21.10.1 BUSINESS OVERVIEW
21.10.2 PRODUCT OFFERINGS
21.11 PRECORDIOR
21.11.1 BUSINESS OVERVIEW
21.11.2 PRODUCT OFFERINGS
21.12 RESAPP HEALTH
21.12.1 BUSINESS OVERVIEW
21.12.2 PRODUCT OFFERINGS
21.13 ROCKLEY PHOTONICS
21.13.1 BUSINESS OVERVIEW
21.13.2 PRODUCT OFFERINGS
21.14 SONDE HEALTH
21.14.1 BUSINESS OVERVIEW
21.14.2 PRODUCT OFFERINGS
21.15 VIVOSENSE
21.15.1 BUSINESS OVERVIEW
21.15.2 PRODUCT OFFERINGS

22 REPORT SUMMARY
22.1 KEY TAKEAWAYS
22.2 STRATEGIC RECOMMENDATIONS

23 QUANTITATIVE SUMMARY
23.1 MARKET BY PRODUCT TYPE
23.1.1 NORTH AMERICA MARKET BY PRODUCT TYPE
23.1.2 EUROPE MARKET BY PRODUCT TYPE
23.1.3 APAC MARKET BY PRODUCT TYPE
23.1.4 LATIN AMERICA MARKET BY PRODUCT TYPE
23.1.5 MIDDLE EAST & AFRICA MARKET BY PRODUCT TYPE
23.2 MARKET BY APPLICATION
23.2.1 NORTH AMERICA MARKET BY APPLICATION
23.2.2 EUROPE MARKET BY APPLICATION
23.2.3 APAC MARKET BY APPLICATION
23.2.4 LATIN AMERICA MARKET BY APPLICATION
23.2.5 MIDDLE EAST & AFRICA MARKET BY APPLICATION
23.3 MARKET BY CLINICAL PRACTICE
23.3.1 NORTH AMERICA MARKET BY CLINICAL PRACTICE
23.3.2 EUROPE MARKET BY CLINICAL PRACTICE
23.3.3 APAC MARKET BY CLINICAL PRACTICE
23.3.4 LATIN AMERICA MARKET BY CLINICAL PRACTICE
23.3.5 MIDDLE EAST & AFRICA MARKET BY CLINICAL PRACTICE
23.4 MARKET BY END-USER
23.4.1 NORTH AMERICA MARKET BY END-USER
23.4.2 EUROPE MARKET BY END-USER
23.4.3 APAC MARKET BY END-USER
23.4.4 LATIN AMERICA MARKET BY END-USER
23.4.5 MIDDLE EAST & AFRICA MARKET BY END-USER
23.5 MARKET BY GEOGRAPHY
23.5.1 WEARABLES & SENSORS MARKET BY GEOGRAPHY
23.5.2 MOBILE APPLICATION & SOFTWARE MARKET BY GEOGRAPHY
23.5.3 CARDIOLOGY MARKET BY GEOGRAPHY
23.5.4 PULMONOLOGY MARKET BY GEOGRAPHY
23.5.5 NEUROLOGY MARKET BY GEOGRAPHY
23.5.6 OTHER MARKET BY GEOGRAPHY
23.5.7 DIAGNOSTIC MARKET BY GEOGRAPHY
23.5.8 MONITORING MARKET BY GEOGRAPHY
23.5.9 PROGNOSTIC MARKET BY GEOGRAPHY
23.5.10 PREDICTIVE MARKET BY GEOGRAPHY
23.5.11 OTHER MARKET BY GEOGRAPHY
23.5.12 HEALTHCARE COMPANIES MARKET BY GEOGRAPHY
23.5.13 HEALTHCARE PROVIDERS MARKET BY GEOGRAPHY
23.5.14 OTHER MARKET BY GEOGRAPHY

24 APPENDIX
24.1 RESEARCH METHODOLOGY
24.2 RESEARCH PROCESS
24.3 REPORT ASSUMPTIONS & CAVEATS
24.3.1 KEY CAVEATS
24.3.2 CURRENCY CONVERSION
24.4 ABBREVIATIONS

EXHIBIT 1 MARKET SIZE CALCULATION APPROACH (2023)
EXHIBIT 2 GLOBAL DIGITAL BIOMARKERS MARKET BY GEOGRAPHY: MARKET OPPORTUNITY OVERVIEW ($ MILLION)
EXHIBIT 3 GLOBAL DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE: MARKET OPPORTUNITY OVERVIEW ($ MILLION)
EXHIBIT 4 GLOBAL DIGITAL BIOMARKERS MARKET BY APPLICATION: MARKET OPPORTUNITY OVERVIEW ($ MILLION)
EXHIBIT 5 GLOBAL DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE: MARKET OPPORTUNITY OVERVIEW ($ MILLION)
EXHIBIT 6 GLOBAL DIGITAL BIOMARKERS MARKET BY END-USER: MARKET OPPORTUNITY OVERVIEW ($ MILLION)
EXHIBIT 7 GLOBAL DIGITAL BIOMARKERS MARKET BY GEOGRAPHY: MARKET SHARE 2023 & 2029 (%)
EXHIBIT 8 GLOBAL DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE: MARKET SHARE 2023 & 2029 (%)
EXHIBIT 9 GLOBAL DIGITAL BIOMARKERS MARKET BY APPLICATION: MARKET SHARE 2023 & 2029 (%)
EXHIBIT 10 GLOBAL DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE: MARKET SHARE 2023 & 2029 (%)
EXHIBIT 11 GLOBAL DIGITAL BIOMARKERS MARKET BY END-USER: MARKET SHARE 2023 & 2029 (%)
EXHIBIT 12 IMPACT OF RISE IN DIGITIZED VIRTUAL CLINICAL RESEARCH
EXHIBIT 13 IMPACT OF INCREASING FOCUS ON DRUG DEVELOPMENT USING DIGITAL BIOMARKERS
EXHIBIT 14 BENEFITS OF DIGITAL BIOMARKERS IN DRUG DEVELOPMENT
EXHIBIT 15 IMPACT OF EXPANDING APPLICATIONS OF DIGITAL BIOMARKERS IN MENTAL HEALTH
EXHIBIT 16 IMPACT OF GROWING COLLABORATIONS & PARTNERSHIPS AMONG VENDORS
EXHIBIT 17 IMPACT OF RISE IN AGING POPULATION & PREVALENCE OF CHRONIC DISEASES
EXHIBIT 18 IMPACT OF ADVANCES IN REMOTE PATIENT MONITORING
EXHIBIT 19 IMPACT OF GROWING CULTURE OF DIGITAL HEALTH & SHIFT TOWARD OUTPATIENT CARE
EXHIBIT 20 IMPACT OF GROWING USE OF WIRELESS & WEARABLE DIGITAL MONITORING TECHNOLOGIES
EXHIBIT 21 IMPACT OF DATA SECURITY & PRIVACY CONCERNS
EXHIBIT 22 IMPACT OF LOW ADOPTION RATE
EXHIBIT 23 IMPACT OF LACK OF REGULATORY STANDARDIZATION
EXHIBIT 24 GLOBAL DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 25 FIVE FORCES ANALYSIS (2023)
EXHIBIT 26 INCREMENTAL GROWTH BY PRODUCT TYPE (2023 & 2029)
EXHIBIT 27 GLOBAL DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023-2029: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 28 GLOBAL DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023-2029: ABSOLUTE GROWTH (%)
EXHIBIT 29 GLOBAL WEARABLES & SENSORS DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 30 GLOBAL WEARABLES & SENSORS DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 31 GLOBAL MOBILE APPLICATION & SOFTWARE DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 32 GLOBAL MOBILE APPLICATION & SOFTWARE DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 33 INCREMENTAL GROWTH BY APPLICATION (2023 & 2029)
EXHIBIT 34 GLOBAL DIGITAL BIOMARKERS MARKET BY APPLICATION 2023-2029: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 35 GLOBAL DIGITAL BIOMARKERS MARKET BY APPLICATION 2023-2029: ABSOLUTE GROWTH (%)
EXHIBIT 36 GLOBAL CARDIOLOGY DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 37 GLOBAL CARDIOLOGY DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 38 GLOBAL PULMONOLOGY DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 39 GLOBAL PULMONOLOGY DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 40 GLOBAL NEUROLOGY DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 GLOBAL NEUROLOGY DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 42 GLOBAL OTHER DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 43 GLOBAL OTHER DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 44 INCREMENTAL GROWTH BY CLINICAL PRACTICE (2023 & 2029)
EXHIBIT 45 GLOBAL DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023-2029: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 46 GLOBAL DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023-2029: ABSOLUTE GROWTH (%)
EXHIBIT 47 GLOBAL DIAGNOSTIC DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL DIAGNOSTIC DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 49 GLOBAL MONITORING DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 50 GLOBAL MONITORING DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 51 GLOBAL PROGNOSTIC DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 52 GLOBAL PROGNOSTIC DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 53 GLOBAL PREDICTIVE DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 54 GLOBAL PREDICTIVE DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 55 GLOBAL OTHER DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 56 GLOBAL OTHER DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 57 INCREMENTAL GROWTH BY END-USER (2023 & 2029)
EXHIBIT 58 GLOBAL DIGITAL BIOMARKERS MARKET BY END-USER 2023-2029: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 59 GLOBAL DIGITAL BIOMARKERS MARKET BY END-USER 2023-2029: ABSOLUTE GROWTH (%)
EXHIBIT 60 GLOBAL HEALTHCARE COMPANIES DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 61 GLOBAL HEALTHCARE COMPANIES DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 62 GLOBAL HEALTHCARE PROVIDERS DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 63 GLOBAL HEALTHCARE PROVIDERS DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 64 GLOBAL OTHER DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 65 GLOBAL OTHER DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 66 INCREMENTAL GROWTH BY GEOGRAPHY (2023 & 2029)
EXHIBIT 67 GLOBAL DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023-2029: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 68 GLOBAL DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023-2029: ABSOLUTE GROWTH (%)
EXHIBIT 69 NORTH AMERICA DIGITAL BIOMARKERS MARKET: KEY COUNTRIES IN 2023 ($ MILLION)
EXHIBIT 70 NORTH AMERICA DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 71 DIGITAL BIOMARKERS MARKET IN NORTH AMERICA 2023–2029 ($ MILLION)
EXHIBIT 72 INCREMENTAL GROWTH IN NORTH AMERICA (2023 & 2029)
EXHIBIT 73 US DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 74 DIGITAL BIOMARKERS MARKET IN CANADA 2023–2029 ($ MILLION)
EXHIBIT 75 EUROPE DIGITAL BIOMARKERS MARKET: KEY COUNTRIES IN 2023 ($ MILLION)
EXHIBIT 76 EUROPE DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 77 DIGITAL BIOMARKERS MARKET IN EUROPE 2023–2029 ($ MILLION)
EXHIBIT 78 INCREMENTAL GROWTH IN EUROPE (2023 & 2029)
EXHIBIT 79 DIGITAL BIOMARKERS MARKET IN GERMANY 2023–2029 ($ MILLION)
EXHIBIT 80 UK DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 81 DIGITAL BIOMARKERS MARKET IN FRANCE 2023–2029 ($ MILLION)
EXHIBIT 82 DIGITAL BIOMARKERS MARKET IN ITALY 2023–2029 ($ MILLION)
EXHIBIT 83 DIGITAL BIOMARKERS MARKET IN SPAIN 2023–2029 ($ MILLION)
EXHIBIT 84 DIGITAL BIOMARKERS MARKET IN RUSSIA 2023–2029 ($ MILLION)
EXHIBIT 85 DIGITAL BIOMARKERS MARKET IN NETHERLANDS 2023–2029 ($ MILLION)
EXHIBIT 86 APAC DIGITAL BIOMARKERS MARKET: KEY COUNTRIES IN 2023 ($ MILLION)
EXHIBIT 87 APAC DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 88 DIGITAL BIOMARKERS MARKET IN APAC 2023–2029 ($ MILLION)
EXHIBIT 89 INCREMENTAL GROWTH IN APAC (2023 & 2029)
EXHIBIT 90 DIGITAL BIOMARKERS MARKET IN JAPAN 2023–2029 ($ MILLION)
EXHIBIT 91 DIGITAL BIOMARKERS MARKET IN CHINA 2023–2029 ($ MILLION)
EXHIBIT 92 DIGITAL BIOMARKERS MARKET IN INDIA 2023–2029 ($ MILLION)
EXHIBIT 93 DIGITAL BIOMARKERS MARKET IN SOUTH KOREA 2023–2029 ($ MILLION)
EXHIBIT 94 DIGITAL BIOMARKERS MARKET IN AUSTRALIA 2023–2029 ($ MILLION)
EXHIBIT 95 LATIN AMERICA DIGITAL BIOMARKERS MARKET: KEY COUNTRIES IN 2023 ($ MILLION)
EXHIBIT 96 LATIN AMERICA DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 97 DIGITAL BIOMARKERS MARKET IN LATIN AMERICA 2023–2029 ($ MILLION)
EXHIBIT 98 INCREMENTAL GROWTH IN LATIN AMERICA (2023 & 2029)
EXHIBIT 99 DIGITAL BIOMARKERS MARKET IN BRAZIL 2023–2029 ($ MILLION)
EXHIBIT 100 DIGITAL BIOMARKERS MARKET IN MEXICO 2023–2029 ($ MILLION)
EXHIBIT 101 DIGITAL BIOMARKERS MARKET IN ARGENTINA 2023–2029 ($ MILLION)
EXHIBIT 102 DIGITAL BIOMARKERS MARKET IN COLOMBIA 2023–2029 ($ MILLION)
EXHIBIT 103 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET: KEY COUNTRIES IN 2023 ($ MILLION)
EXHIBIT 104 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET 2023-2029: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 105 DIGITAL BIOMARKERS MARKET IN MIDDLE EAST & AFRICA 2023–2029 ($ MILLION)
EXHIBIT 106 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA (2023 & 2029)
EXHIBIT 107 DIGITAL BIOMARKERS MARKET IN TURKEY 2023–2029 ($ MILLION)
EXHIBIT 108 DIGITAL BIOMARKERS MARKET IN SAUDI ARABIA 2023–2029 ($ MILLION)
EXHIBIT 109 UAE DIGITAL BIOMARKERS MARKET 2023–2029 ($ MILLION)
EXHIBIT 110 DIGITAL BIOMARKERS MARKET IN SOUTH AFRICA 2023–2029 ($ MILLION)
EXHIBIT 111 VENDORS OFFERING DIGITAL BIOMARKERS: MARKET DOMINANCE ANALYSIS
EXHIBIT 112 VENDORS OFFERING COMMERCIAL DIGITAL BIOMARKERS: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 113 KEY CAVEATS

LIST OF TABLES

TABLE 1 GLOBAL DIGITAL BIOMARKERS MARKET BY GEOGRAPHY: MARKET SIZE 2023–2029 ($ MILLION)
TABLE 2 GLOBAL DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE: MARKET SIZE 2023–2029 ($ MILLION)
TABLE 3 GLOBAL DIGITAL BIOMARKERS MARKET BY APPLICATION: MARKET SIZE 2023–2029 ($ MILLION)
TABLE 4 GLOBAL DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE: MARKET SIZE 2023–2029 ($ MILLION)
TABLE 5 GLOBAL DIGITAL BIOMARKERS MARKET BY END-USER: MARKET SIZE 2023–2029 ($ MILLION)
TABLE 6 COMPARISON OF DIGITAL BIOMARKERS AND TRADITIONAL BIOMARKERS
TABLE 7 EXAMPLES OF COMPANY’S DIGITAL BIOMARKERS FOCUSING ON CHRONIC CONDITIONS
TABLE 8 GLOBAL WEARABLES & SENSORS DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 9 GLOBAL WEARABLES & SENSORS DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 10 GLOBAL MOBILE APPLICATION & SOFTWARE DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 11 GLOBAL MOBILE APPLICATION & SOFTWARE DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 12 GLOBAL CARDIOLOGY DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 13 GLOBAL CARDIOLOGY DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 14 GLOBAL PULMONOLOGY DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 15 GLOBAL PULMONOLOGY DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 16 GLOBAL NEUROLOGY DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 17 GLOBAL NEUROLOGY DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 18 GLOBAL OTHER DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 19 GLOBAL OTHER DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 20 GLOBAL DIAGNOSTIC DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 21 GLOBAL DIAGNOSTIC DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 22 GLOBAL MONITORING DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 23 GLOBAL MONITORING DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 24 GLOBAL PROGNOSTIC DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 25 GLOBAL PROGNOSTIC DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 26 GLOBAL PREDICTIVE DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 27 GLOBAL PREDICTIVE DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 28 GLOBAL OTHER DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 29 GLOBAL OTHER DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 30 GLOBAL HEALTHCARE COMPANIES DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 31 GLOBAL HEALTHCARE COMPANIES DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 32 GLOBAL HEALTHCARE PROVIDERS DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 33 GLOBAL HEALTHCARE PROVIDERS DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 34 GLOBAL OTHER DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 35 GLOBAL OTHER DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 36 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 ($ MILLION)
TABLE 37 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 (%)
TABLE 38 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 39 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 (%)
TABLE 40 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 ($ MILLION)
TABLE 41 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 (%)
TABLE 42 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 43 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 (%)
TABLE 44 EUROPE DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 ($ MILLION)
TABLE 45 EUROPE DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 (%)
TABLE 46 EUROPE DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 47 EUROPE DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 (%)
TABLE 48 EUROPE DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 ($ MILLION)
TABLE 49 EUROPE DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 (%)
TABLE 50 EUROPE DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 51 EUROPE DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 (%)
TABLE 52 APAC DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 ($ MILLION)
TABLE 53 APAC DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 (%)
TABLE 54 APAC DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 55 APAC DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 (%)
TABLE 56 APAC DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 ($ MILLION)
TABLE 57 APAC DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 (%)
TABLE 58 APAC DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 59 APAC DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 (%)
TABLE 60 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 ($ MILLION)
TABLE 61 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 (%)
TABLE 62 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 63 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 (%)
TABLE 64 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 ($ MILLION)
TABLE 65 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 (%)
TABLE 66 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 67 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 (%)
TABLE 68 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 ($ MILLION)
TABLE 69 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 (%)
TABLE 70 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 71 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 (%)
TABLE 72 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 ($ MILLION)
TABLE 73 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 (%)
TABLE 74 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 75 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 (%)
TABLE 76 ACTIGRAPH: MAJOR PRODUCT OFFERINGS
TABLE 77 ALIVECOR: MAJOR PRODUCT OFFERINGS
TABLE 78 AMGEN: MAJOR PRODUCT OFFERINGS
TABLE 79 BIOGEN: MAJOR PRODUCT OFFERINGS
TABLE 80 KONEKSA HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 81 ADHERIUM: MAJOR PRODUCT OFFERINGS
TABLE 82 AURAL ANALYTICS: MAJOR PRODUCT OFFERINGS
TABLE 83 BIOFOURMIS: MAJOR PRODUCT OFFERINGS
TABLE 84 CLARIO: MAJOR PRODUCT OFFERINGS
TABLE 85 EMPATICA: MAJOR PRODUCT OFFERINGS
TABLE 86 FEEL THERAPEUTICS: MAJOR PRODUCT OFFERINGS
TABLE 87 GERO.AI: MAJOR PRODUCT OFFERINGS
TABLE 88 IXICO: MAJOR PRODUCT OFFERINGS
TABLE 89 OBVIO HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 90 OWKIN: MAJOR PRODUCT OFFERINGS
TABLE 91 PRECORDIOR: MAJOR PRODUCT OFFERINGS
TABLE 92 RESAPP HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 93 ROCKLEY PHOTONICS: MAJOR PRODUCT OFFERINGS
TABLE 94 SONDE HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 95 VIVOSENSE: MAJOR PRODUCT OFFERINGS
TABLE 96 GLOBAL DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 ($ MILLION)
TABLE 97 GLOBAL DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 (%)
TABLE 98 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 ($ MILLION)
TABLE 99 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 (%)
TABLE 100 EUROPE DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 ($ MILLION)
TABLE 101 EUROPE DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 (%)
TABLE 102 APAC DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 ($ MILLION)
TABLE 103 APAC DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 (%)
TABLE 104 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 ($ MILLION)
TABLE 105 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 (%)
TABLE 106 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 ($ MILLION)
TABLE 107 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY PRODUCT TYPE 2023−2029 (%)
TABLE 108 GLOBAL DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 109 GLOBAL DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 (%)
TABLE 110 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 111 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 (%)
TABLE 112 EUROPE DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 113 EUROPE DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 (%)
TABLE 114 APAC DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 115 APAC DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 (%)
TABLE 116 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 117 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 (%)
TABLE 118 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 ($ MILLION)
TABLE 119 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY APPLICATION 2023−2029 (%)
TABLE 120 GLOBAL DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 ($ MILLION)
TABLE 121 GLOBAL DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 (%)
TABLE 122 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 ($ MILLION)
TABLE 123 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 (%)
TABLE 124 EUROPE DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 ($ MILLION)
TABLE 125 EUROPE DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 (%)
TABLE 126 APAC DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 ($ MILLION)
TABLE 127 APAC DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 (%)
TABLE 128 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 ($ MILLION)
TABLE 129 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 (%)
TABLE 130 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 ($ MILLION)
TABLE 131 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY CLINICAL PRACTICE 2023−2029 (%)
TABLE 132 GLOBAL DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 133 GLOBAL DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 (%)
TABLE 134 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 135 NORTH AMERICA DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 (%)
TABLE 136 EUROPE DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 137 EUROPE DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 (%)
TABLE 138 APAC DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 139 APAC DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 (%)
TABLE 140 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 141 LATIN AMERICA DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 (%)
TABLE 142 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 ($ MILLION)
TABLE 143 MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET BY END-USER 2023−2029 (%)
TABLE 144 GLOBAL DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 145 GLOBAL DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 146 GLOBAL WEARABLES & SENSORS DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 147 GLOBAL WEARABLES & SENSORS DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 148 GLOBAL MOBILE APPLICATION & SOFTWARE DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 149 GLOBAL MOBILE APPLICATION & SOFTWARE DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 150 GLOBAL CARDIOLOGY DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 151 GLOBAL CARDIOLOGY DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 152 GLOBAL PULMONOLOGY DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 153 GLOBAL PULMONOLOGY DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 154 GLOBAL NEUROLOGY DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 155 GLOBAL NEUROLOGY DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 156 GLOBAL OTHER DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 157 GLOBAL OTHER DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 158 GLOBAL DIAGNOSTIC DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 159 GLOBAL DIAGNOSTIC DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 160 GLOBAL MONITORING DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 161 GLOBAL MONITORING DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 162 GLOBAL PROGNOSTIC DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 163 GLOBAL PROGNOSTIC DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 164 GLOBAL PREDICTIVE DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 165 GLOBAL PREDICTIVE DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 166 GLOBAL OTHER DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 167 GLOBAL OTHER DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 168 GLOBAL HEALTHCARE COMPANIES DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 169 GLOBAL HEALTHCARE COMPANIES DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 170 GLOBAL HEALTHCARE PROVIDERS DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 171 GLOBAL HEALTHCARE PROVIDERS DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 172 GLOBAL OTHER DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 ($ MILLION)
TABLE 173 GLOBAL OTHER DIGITAL BIOMARKERS MARKET BY GEOGRAPHY 2023−2029 (%)
TABLE 174 CURRENCY CONVERSION (2017−2023)

Select a license type that suits your business needs

single-user Single User Licence
$4200.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4999.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5999.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$2000.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date